Cancer Genetics Inc. (NASDAQ:CGIX) traded up 4.1% on Wednesday . The stock traded as high as $2.07 and last traded at $2.02, with a volume of 105,073 shares. The stock had previously closed at $1.94.

Several equities research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Cancer Genetics from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research note on Wednesday, May 11th. Janney Montgomery Scott reiterated a “neutral” rating on shares of Cancer Genetics in a report on Friday, March 11th. Finally, Aegis boosted their price target on shares of Cancer Genetics from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, March 15th.

The company has a 50-day moving average of $2.08 and a 200-day moving average of $2.45. The stock’s market capitalization is $27.58 million.

Cancer Genetics (NASDAQ:CGIX) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The business had revenue of $6.10 million for the quarter, compared to analyst estimates of $6.95 million. During the same quarter last year, the firm earned ($0.44) earnings per share. The firm’s quarterly revenue was up 38.6% compared to the same quarter last year. On average, equities analysts forecast that Cancer Genetics Inc. will post ($1.26) earnings per share for the current fiscal year.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.